Belgian atopic dermatitis guidelines.

IF 1.6 4区 医学 Q2 Medicine Acta Clinica Belgica Pub Date : 2024-02-01 Epub Date: 2024-01-02 DOI:10.1080/17843286.2023.2285576
Hilde Lapeere, Reinhart Speeckaert, Marie Baeck, Bita Dezfoulian, Julien Lambert, Pierre-Paul Roquet-Gravy, Annelies Stockman, Jonathan White, Francisca Castelijns, Jan Gutermuth
{"title":"Belgian atopic dermatitis guidelines.","authors":"Hilde Lapeere, Reinhart Speeckaert, Marie Baeck, Bita Dezfoulian, Julien Lambert, Pierre-Paul Roquet-Gravy, Annelies Stockman, Jonathan White, Francisca Castelijns, Jan Gutermuth","doi":"10.1080/17843286.2023.2285576","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"62-74"},"PeriodicalIF":1.6000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2023.2285576","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
比利时特应性皮炎指南。
特应性皮炎(AD)是最常见、最麻烦、最难治疗的皮肤病之一。最近引入的新的系统性治疗方法彻底改变了阿尔茨海默病的管理。本指南的目的是为特应性皮炎患者的管理提供循证建议,这些建议易于在临床实践中实施。这些建议是由11名比利时AD专家提出的。收集了所有专家对拟议声明的意见,然后进行了在线投票。最相关的策略,管理和治疗AD在比利时的卫生保健景观的背景下进行了讨论。一般措施,患者教育和适当的局部治疗仍然是AD管理的基石。对于中度至重度AD,生物制剂和JAK抑制剂的引入显示出前所未有的疗效,尽管目前仅限于满足报销标准的患者亚组。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Clinica Belgica
Acta Clinica Belgica 医学-医学:内科
CiteScore
2.90
自引率
0.00%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
期刊最新文献
Flemish consensus statement on the prevention, diagnosis and treatment of urinary tract infections in older nursing home residents. Validation of EUCAST rapid antimicrobial susceptibility testing directly from positive blood cultures in a non-automated lab setting. A multimodal treatment of basilar artery re-occlusion - case report. 'Iatrogenic septic pit': empyema, a rare complication after endobronchial valve placement. The first reported familial case of statin-induced immune-mediated necrotizing myopathy associated with anti-hydroxy-3-methylglutaryl-CoA reductase autoantibodies and HLA DRB1*11:01
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1